Imugene achieves phase-II clinical trial milestone for HER-Vaxx cancer immunotherapy
The important clinical endpoint of Progression Free Survival (PFS) has been met after the statistically significant required number of PFS events has occurred.
Company
Imugene Ltd
ASX:IMU
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. The company's unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Imugene is supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
224 stories · page 7 of 12
Imugene presents new data on anti-cancer treatments during prestigious AACR annual meeting
The company presented on the HER-Vaxx cancer immunotherapy program and the CF33 oncolytic virus program during the meeting.
Imugene secures A$0.20 price target from Roth Capital Partners
The company’s cohort review committee has confirmed that its Phase 1 NSCLC trial for checkpoint immunotherapy candidate PD1-Vaxx may proceed to the third and final dose cohort.
Imugene proceeds to third and final highest dose cohort for Phase I clinical trial of PD1-Vaxx, shares up
PD1-Vaxx has been deemed safe with no dose-limiting toxicities (DLTs) and no serious adverse reactions observed at mid-dose (50μg) level and will now escalate to the final highest dose (100μg) cohort.
Imugene secures BUY rating and target price of A$0.20 from Roth Capital Partners
In the near-term, the company expects to release the HER-Vaxx results, progress phase 1 of the PD1-Vaxx clinical trial and start the VAXinia and CHECKvacc clinical programs in the US.
Imguene to present on CF33 and HER-Vaxx immunotherapy programs at American Association for Cancer Research annual meeting
The company will present on the CF33 oncolytic virus program and on the HER-Vaxx cancer immunotherapy program during the prestigious association's annual meeting.
Imugene doses first patient in cohort-2 in phase-I clinical trial of PD1-Vaxx
The company is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Imugene receives approval for phase I clinical trial of new checkpoint immunotherapy candidate PD1-VAX
The CRC unanimously agreed that PD1-Vaxx is safe with no dose-limiting toxicities (DLTs) and has recommended to proceed to the next dose escalation due to safety and tolerability.
Imugene completes recruitment to HER-VAXX Phase 2 gastric cancer trial
The Phase 2 trial represents a clinical proof-of-concept for HER-Vaxx to indicate that B-cell activating immunotherapy platform can induce clinically active antibody responses.
Imugene completes enrolment of first cohort of patients in Phase I clinical trial of checkpoint immunotherapy candidate PD1-Vaxx
The clinical-stage immune-oncology company has enrolled the first three patients in the first low dose PD1-Vaxx cohort with non-small cell lung cancer.
Imugene boosts cash balance after receiving $4.82 million R&D tax incentive
Receiving the $4,823,466 million in additional funding will further support the company's commercial and clinical milestones.
Imugene Limited phase II trial is highly encouraging: Bell Potter Securities
Bell Potter has raised its valuation of Imugene to 17 cents from 5 cents and has maintained its buy (speculative) recommendation.
Imugene doses first patient in Phase 1 clinical trial of checkpoint immunotherapy candidate PD1-Vaxx for lung cancer
The first-in-human, Phase 1, multi-centre, dose-escalation study of PD1-Vaxx is recruiting patients with non-small cell lung cancer.
Imugene up 20% on unveiling positive interim data from ongoing Phase 2 study of HER-Vaxx in advanced gastric cancer
The IDMC provided guidance that it is scientifically and ethically appropriate to reduce the overall number of patients required to complete the study, given the strong signal observed in the data.
Imugene receives FDA IND approval for phase-1 clinical trial of new checkpoint immunotherapy PD1-Vaxx in USA
US FDA approval of the IND allows Imugene to initiate patient recruitment and dosing in its USA Phase I clinical study in non-small cell lung cancer (NSCLC) patients.
Imugene fully funded to progress four clinical trials in the near-term
During the September quarter, the clinical-stage immuno-oncology company continued to progress clinical programs and remains well-funded to cater for an expected increase in expenditures.
Imugene has a high likelihood of clinical success: Roth Capital Partners
Imugene's oncolytic viruses are designed to infect, replicate in, and kill cancer cells, leaving healthy cells essentially unharmed.
Imugene higher on being granted cancer growth factor immunotherapy combination patent in US
The company recently boosted its balance sheet with a $5.7 million underwriting agreement to support four continuing clinical programs - CF33, PD1, Vaxx and HER-Vaxx as well as provide funding for IP and milestone payments.
Imugene bolsters executive team with appointment of Dr Rita Laeufle as chief medical officer
The company recently entered into an agreement to underwrite outstanding listed options which provides holders with an option to purchase shares in the company at 2.6 cents per share.
Imugene boosts balance sheet with $5.7 million option underwriting agreement
The agreement with Bell Potter further strengthens the company’s financial position building on the existing cash balance of $30.1 million as of June 30, 2020.